VKH
TARA icon

Virtu KCG Holdings’s Protara Therapeutics TARA Stock Holding History

Virtu KCG Holdings’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$20K Sell
323
-594
-65% -$33.3K ﹤0.01% 2723
2017
Q1 		$64K Buy
917
+126
+16% +$9.42K ﹤0.01% 2788
2016
Q4 		$60K Buy
+791
New +$250K ﹤0.01% 3048

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu KCG Holdings's TARA Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Protara Therapeutics (TARA) stake by 65% in Q2 2017, selling an estimated $33.3K and leaving 323 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #2723.

Virtu KCG Holdings first reported a position in TARA in Q4 2016 and has held it in 3 quarters since. The position peaked at $64K in Q1 2017. 28 funds tracked by Wall St. Rank hold TARA as of Q2 2017.

  • Virtu KCG Holdings held 323 shares of Protara Therapeutics worth $20K as of Q2 2017.
  • Virtu KCG Holdings sold 594 Protara Therapeutics shares in Q2 2017, an estimated $33.3K.
  • Protara Therapeutics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2723 holding.
  • Virtu KCG Holdings first reported a position in Protara Therapeutics in Q4 2016 and has held it in 3 quarters since.
  • Virtu KCG Holdings's Protara Therapeutics position peaked at $64K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.